Adrenoleukodystrophy (Adrenomyeloneuropathy/ Schilder-Addison Complex) Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update

September 2022 | 159 pages | ID: A6F521B30D41EN
Global Markets Direct

Abstracts

Adrenoleukodystrophy (Adrenomyeloneuropathy/Schilder-Addison Complex) Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update

SUMMARY

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Adrenoleukodystrophy - Drugs In Development, 2022, provides an overview of the Adrenoleukodystrophy (Genetic Disorders) pipeline landscape.

Adrenoleukodystrophy is a disorder that occurs most often in males. It mainly affects the nervous system and the adrenal glands, which are small glands located on top of each kidney. Abetalipoproteinemia is also a kind of Adrenoleukodystrophy (Adrenomyeloneuropathy/Schilder-Addison Complex) Bassen-Kornzweig syndrome is a rare disease passed down through families in which a person is unable to fully absorb dietary fats through the intestines. The disease is caused by a defect in gene that tells the body to create lipoproteins. It is sympotomized by curvature of spine, muscle weakness, decrease of vision over time. Treatment involves large doses of vitamin supplements containing fat-soluble vitamins.

REPORT HIGHLIGHTS

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Adrenoleukodystrophy - Drugs In Development, 2022, provides comprehensive information on the therapeutics under development for Adrenoleukodystrophy (Genetic Disorders), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Adrenoleukodystrophy (Genetic Disorders) pipeline guide also reviews of key players involved in therapeutic development for Adrenoleukodystrophy (X-Linked Adrenoleukodystrophy (X-ALD)) and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies/Universities/Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, Preclinical, Discovery and Unknown stages are 1, 2, 2, 4, 4, 2 and 1 respectively. Similarly, the Universities portfolio in Phase II, Phase I and Preclinical stages comprises 2, 1 and 2 molecules, respectively.

Adrenoleukodystrophy (Genetic Disorders) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

SCOPE

• The pipeline guide provides a snapshot of the global therapeutic landscape of Adrenoleukodystrophy (Genetic Disorders).
• The pipeline guide reviews pipeline therapeutics for Adrenoleukodystrophy (Genetic Disorders) by companies and universities/research institutes based on information derived from company and industry-specific sources.
• The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
• The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
• The pipeline guide reviews key companies involved in Adrenoleukodystrophy (Genetic Disorders) therapeutics and enlists all their major and minor projects.
• The pipeline guide evaluates Adrenoleukodystrophy (Genetic Disorders) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
• The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
• The pipeline guide reviews latest news related to pipeline therapeutics for Adrenoleukodystrophy (Genetic Disorders)

REASONS TO BUY

• Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
• Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
• Find and recognize significant and varied types of therapeutics under development for Adrenoleukodystrophy (Genetic Disorders).
• Classify potential new clients or partners in the target demographic.
• Develop tactical initiatives by understanding the focus areas of leading companies.
• Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
• Formulate corrective measures for pipeline projects by understanding Adrenoleukodystrophy (Genetic Disorders) pipeline depth and focus of Indication therapeutics.
• Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
• Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Contents

Introduction
Global Markets Direct Report Coverage
Adrenoleukodystrophy (X-Linked Adrenoleukodystrophy (X-ALD)) - Overview
Adrenoleukodystrophy (X-Linked Adrenoleukodystrophy (X-ALD)) - Therapeutics Development
Pipeline Overview
Pipeline by Companies
Pipeline by Universities/Institutes
Products under Development by Companies
Products under Development by Universities/Institutes
Adrenoleukodystrophy (X-Linked Adrenoleukodystrophy (X-ALD)) - Therapeutics Assessment
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Adrenoleukodystrophy (X-Linked Adrenoleukodystrophy (X-ALD)) - Companies Involved in Therapeutics Development
Adrenoleukodystrophy (X-Linked Adrenoleukodystrophy (X-ALD)) - Drug Profiles
Adrenoleukodystrophy (X-Linked Adrenoleukodystrophy (X-ALD)) - Dormant Projects
Adrenoleukodystrophy (X-Linked Adrenoleukodystrophy (X-ALD)) - Discontinued Products
Adrenoleukodystrophy (X-Linked Adrenoleukodystrophy (X-ALD)) - Product Development Milestones
Featured News & Press Releases
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

List Of Tables

LIST OF TABLES

Number of Products under Development for Adrenoleukodystrophy (X-Linked Adrenoleukodystrophy (X-ALD)), 2022
Number of Products under Development by Companies, 2022
Number of Products under Development by Universities/Institutes, 2022
Products under Development by Companies, 2022
Products under Development by Companies, 2022 (Contd..1)
Products under Development by Universities/Institutes, 2022
Number of Products by Stage and Target, 2022
Number of Products by Stage and Mechanism of Action, 2022
Number of Products by Stage and Route of Administration, 2022
Number of Products by Stage and Molecule Type, 2022
Adrenoleukodystrophy (X-Linked Adrenoleukodystrophy (X-ALD)) - Pipeline by Apteeus SAS, 2022
Adrenoleukodystrophy (X-Linked Adrenoleukodystrophy (X-ALD)) - Pipeline by Ashvattha Therapeutics LLC, 2022
Adrenoleukodystrophy (X-Linked Adrenoleukodystrophy (X-ALD)) - Pipeline by Autobahn Therapeutics Inc, 2022
Adrenoleukodystrophy (X-Linked Adrenoleukodystrophy (X-ALD)) - Pipeline by bluebird bio Inc, 2022
Adrenoleukodystrophy (X-Linked Adrenoleukodystrophy (X-ALD)) - Pipeline by Celularity Inc, 2022
Adrenoleukodystrophy (X-Linked Adrenoleukodystrophy (X-ALD)) - Pipeline by Imstem Biotechnology Inc, 2022
Adrenoleukodystrophy (X-Linked Adrenoleukodystrophy (X-ALD)) - Pipeline by MedDay SA, 2022
Adrenoleukodystrophy (X-Linked Adrenoleukodystrophy (X-ALD)) - Pipeline by Minoryx Therapeutics sl, 2022
Adrenoleukodystrophy (X-Linked Adrenoleukodystrophy (X-ALD)) - Pipeline by Orpheris Inc, 2022
Adrenoleukodystrophy (X-Linked Adrenoleukodystrophy (X-ALD)) - Pipeline by Poxel SA, 2022
Adrenoleukodystrophy (X-Linked Adrenoleukodystrophy (X-ALD)) - Pipeline by ReceptoPharm Inc, 2022
Adrenoleukodystrophy (X-Linked Adrenoleukodystrophy (X-ALD)) - Pipeline by SwanBio Therapeutics Ltd, 2022
Adrenoleukodystrophy (X-Linked Adrenoleukodystrophy (X-ALD)) - Pipeline by Vigil Neuroscience Inc, 2022
Adrenoleukodystrophy (X-Linked Adrenoleukodystrophy (X-ALD)) - Pipeline by Viking Therapeutics Inc, 2022
Adrenoleukodystrophy (X-Linked Adrenoleukodystrophy (X-ALD)) - Dormant Projects, 2022
Adrenoleukodystrophy (X-Linked Adrenoleukodystrophy (X-ALD)) - Discontinued Products, 2022

List Of Figures

LIST OF FIGURES

Number of Products under Development for Adrenoleukodystrophy (X-Linked Adrenoleukodystrophy (X-ALD)), 2022
Number of Products under Development by Companies, 2022
Number of Products under Development by Universities/Institutes, 2022
Number of Products by Top 10 Targets, 2022
Number of Products by Stage and Top 10 Targets, 2022
Number of Products by Top 10 Mechanism of Actions, 2022
Number of Products by Stage and Top 10 Mechanism of Actions, 2022
Number of Products by Top 10 Routes of Administration, 2022
Number of Products by Stage and Top 10 Routes of Administration, 2022
Number of Products by Top 10 Molecule Types, 2022
Number of Products by Stage and Top 10 Molecule Types, 2022